GCP
FHTX icon

GSA Capital Partners’s Foghorn Therapeutics FHTX Stock Holding History

GSA Capital Partners’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,855
Closed -$147K – 1751
2024
Q1 		$147K Sell
21,855
-19,440
-47% -$108K 0.01% 1450
2023
Q4 		$266K Buy
+41,295
New +$178K 0.02% 1178

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

GSA Capital Partners's FHTX Position: Q2 2024 in Review

GSA Capital Partners sold out of Foghorn Therapeutics (FHTX) in Q2 2024, closing a stake of 21,855 shares — an estimated $147K sold.

GSA Capital Partners first reported a position in FHTX in Q4 2023 and held it in 2 quarters. The position peaked at $266K in Q4 2023. 72 funds tracked by Wall St. Rank hold FHTX as of Q2 2024.

  • GSA Capital Partners reported no remaining Foghorn Therapeutics position as of Q2 2024 after selling out during the quarter.
  • GSA Capital Partners sold 21,855 Foghorn Therapeutics shares in Q2 2024, an estimated $147K.
  • GSA Capital Partners first reported a position in Foghorn Therapeutics in Q4 2023 and held it in 2 quarters.
  • GSA Capital Partners's Foghorn Therapeutics position peaked at $266K in Q4 2023.
  • 72 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2024.

Based on GSA Capital Partners's 13F filing for Q2 2024, filed 15 Aug 2024.